Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim

NCT01143038 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01143038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01143038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
December 26, 2013
Enrollment
75 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura